TYPE OF CYP450 2C19 GENE METABOLIZERS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN THE REPUBLIC OF NORTH MACEDONIA -A PILOT STUDY

• DOI: 10.55302/jms2253078s
• Publication Date: 2023-01-09T12:08:53Z
• Authors: Tamara Savevska; Olivija Efinska M...; Kristina Stamatovska; Magdalena Otljanska; Frosina Arnaudova; Matej Otljanski; Meri Kirijas; Teodora Brnjarche...; Olgica Sibinovska; Gorjan Milanovski; Stefani Iljoska; Boban Dobrevski; Todor Arsov; Aleksandar Petlic...; Dejan Kiril Trajkov

Clopidogrel has an antiplatelet effect, which is used to reduce the risk of myocardial infarction and stroke in high-risk patients context primary prophylaxis. In body it subjected metabolism by liver enzyme system CYP450. this project, laboratory conditions have been established determine polymorphisms CYP450 2C19 gene. The structure gene type metabolizer determined.This study included 42 heart with St. post PCI, mean age 65-9.7 years, treated 75 mg daily. following were examined: c.681G> A; c.636G> c.1A> G; c.1297C> T; c.395G> c.819 + 2T> c.358T> C; c.-806C> T. Appropriate for precise determination metabolizer. results showed that our largest number occur at position A leads creation intermediate metabolizer, while polymorphism T ultrafast metabolite. occurs gene, Because this, before starting therapy necessary first what clopidogrel metabolizers they are whether possess LF or GF alleles. Key words: clopidogrel, metabolite, polymorphisms,